marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2023-Q2
added 08-10-2023
Infinity Pharmaceuticals Balance Sheet 2011-2024 | INFI
Annual Balance Sheet Infinity Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-37.4 M | -79.3 M | 21.8 M | 27.6 M | -48.6 M | -28.6 M | -54.5 M | -168 M | -292 M | -55 M | -176 M | 104 M |
Long Term Debt |
324 K | 917 K | 49.6 M | 29.6 M | - | - | - | - | - | 6.46 M | - | 37.6 M |
Long Term Debt Current |
593 K | 519 K | 489 K | 381 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 51.3 M | 31.6 M | 38 K | 28 K | 19.3 M | 120 M | 105 M | 7.23 M | 6.79 M | 80.1 M |
Total Current Liabilities |
13.6 M | 13.3 M | 11 M | 9.7 M | 7.72 M | 11.6 M | 23.9 M | 70.1 M | 54.9 M | 22.2 M | 18.7 M | 29 M |
Total Liabilities |
61.2 M | 63.2 M | 62.3 M | 41.3 M | 7.76 M | 11.6 M | 43.2 M | 190 M | 160 M | 29.4 M | 25.5 M | 109 M |
Deferred Revenue |
- | - | - | - | - | - | - | 35.4 M | 24.5 M | - | - | 4.21 M |
Retained Earnings |
-856 M | -812 M | -766 M | -726 M | -679 M | -668 M | -626 M | -596 M | -467 M | -450 M | -323 M | -269 M |
Total Assets |
42.2 M | 84.8 M | 39.3 M | 49 M | 60.2 M | 59.4 M | 126 M | 289 M | 369 M | 231 M | 336 M | 124 M |
Cash and Cash Equivalents |
38.3 M | 80.7 M | 28.6 M | 22.3 M | 48.6 M | 34.6 M | 74.1 M | 188 M | 307 M | 68.1 M | 176 M | 24.2 M |
Book Value |
-19.1 M | 21.6 M | -23 M | 7.73 M | 52.5 M | 47.7 M | 82.5 M | 98.6 M | 209 M | 201 M | 310 M | 15.4 M |
Total Shareholders Equity |
-19.1 M | 21.6 M | -23 M | 7.73 M | 52.5 M | 47.7 M | 82.5 M | 98.6 M | 209 M | 201 M | 310 M | 15.4 M |
All numbers in USD currency
Quarterly Balance Sheet Infinity Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 164 K | 324 K | 480 K | 633 K | 777 K | 917 K | 1.05 M | 1.19 M | 1.31 M | 1.44 M | 1.44 M | 1.44 M | 1.44 M | 1.93 M | 1.93 M | 1.93 M | 1.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
58.6 M | 58.3 M | 61.2 M | 62.5 M | 63 M | 62.6 M | 63.2 M | 62.5 M | 61.1 M | 60.4 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 41.3 M | 41.3 M | 41.3 M | 41.3 M | 7.76 M | 7.76 M | 7.76 M | 7.76 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 43.2 M | 43.2 M | 43.2 M | 43.2 M | 190 M | 190 M | 190 M | 190 M | 160 M | 160 M | 160 M | 160 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 25.5 M | 25.5 M | 25.5 M | 25.5 M | 109 M | 109 M | 109 M | 109 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.3 M | 35.4 M | 35.4 M | 35.4 M | 35.4 M | 24.5 M | 24.5 M | 24.5 M | 24.5 M | - | - | - | - | - | - | 14 M | 7.58 M | 4.22 M | 4.22 M | 4.22 M | 4.22 M |
Retained Earnings |
-877 M | -867 M | -856 M | -847 M | -836 M | -824 M | -812 M | -800 M | -789 M | -778 M | -766 M | -766 M | -766 M | -766 M | -726 M | -726 M | -726 M | -726 M | -679 M | -679 M | -679 M | -679 M | -668 M | -668 M | -668 M | -668 M | -626 M | -626 M | -626 M | -626 M | -596 M | -596 M | -596 M | -596 M | -467 M | -467 M | -467 M | -467 M | -450 M | -450 M | -450 M | -450 M | -323 M | -323 M | -323 M | -323 M | -269 M | -269 M | -269 M | -269 M |
Total Assets |
21.2 M | 30 M | 42.2 M | 51.6 M | 61.9 M | 72.6 M | 84.8 M | 94.6 M | 103 M | 112 M | 39.3 M | 39.3 M | 39.3 M | 39.3 M | 49 M | 49 M | 49 M | 49 M | 60.2 M | 60.2 M | 60.2 M | 60.2 M | 59.4 M | 59.4 M | 59.4 M | 59.4 M | 126 M | 126 M | 126 M | 126 M | 289 M | 289 M | 289 M | 289 M | 369 M | 369 M | 369 M | 369 M | 231 M | 231 M | 231 M | 231 M | 336 M | 336 M | 336 M | 336 M | 124 M | 124 M | 124 M | 124 M |
Cash and Cash Equivalents |
17.7 M | 25.7 M | 38.3 M | 47.2 M | 45.8 M | 53.1 M | 80.7 M | 90.1 M | 97.3 M | 107 M | 28.9 M | 28.6 M | 28.6 M | 28.6 M | 22.3 M | 22.3 M | 22.3 M | 22.3 M | 48.6 M | 48.6 M | 48.6 M | 48.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 74.1 M | 74.1 M | 74.1 M | 74.1 M | 188 M | 188 M | 188 M | 188 M | 307 M | 307 M | 307 M | 307 M | 68.1 M | 68.1 M | 68.1 M | 68.1 M | 176 M | 176 M | 176 M | 176 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M |
Book Value |
-37.4 M | -28.3 M | -19.1 M | -10.9 M | -1.11 M | 9.98 M | 21.6 M | 32.1 M | 41.5 M | 52 M | -23 M | -23 M | -23 M | -23 M | 7.73 M | 7.73 M | 7.73 M | 7.73 M | 52.5 M | 52.5 M | 52.5 M | 52.5 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | 98.6 M | 98.6 M | 98.6 M | 98.6 M | 209 M | 209 M | 209 M | 209 M | 201 M | 201 M | 201 M | 201 M | 310 M | 310 M | 310 M | 310 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M |
Total Shareholders Equity |
-37.4 M | -28.3 M | -19.1 M | -10.9 M | -1.11 M | 9.98 M | 21.6 M | 32.1 M | 41.5 M | 52 M | -23 M | -23 M | -23 M | -23 M | 7.73 M | 7.73 M | 7.73 M | 7.73 M | 52.5 M | 52.5 M | 52.5 M | 52.5 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | 98.6 M | 98.6 M | 98.6 M | 98.6 M | 209 M | 209 M | 209 M | 209 M | 201 M | 201 M | 201 M | 201 M | 310 M | 310 M | 310 M | 310 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M |
All numbers in USD currency